Abstract
The 7-valent pneumococcal polysaccharide-protein (CRM(197)) conjugate vaccine (PCV-7) was licensed based on clinical efficacy trials using the four-dose schedule of three infant doses and a booster dose in the second year of life (3 + 1). An assessment of PCV-7 immunogenicity in studies evaluating two infant doses with a booster (2 + 1) showed similar immunogenicity for the 2 + 1 and 3 + 1 schedules, with the exception of lower post-dose two responses for serotypes 6B and 23F, compared with a three-dose primary series. The 2 + 1 PCV-7 schedule has been shown to be effective in controlling pneumococcal disease in several countries, as used in national immunization programs that are marked in particular by good uptake, compliance with the booster dose and application of a catch-up program.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Bacterial / blood
-
Bacterial Proteins / administration & dosage
-
Bacterial Proteins / immunology*
-
Canada
-
Europe
-
Heptavalent Pneumococcal Conjugate Vaccine
-
Humans
-
Immunization Programs
-
Immunization Schedule
-
Immunization, Secondary
-
Infant
-
Pneumococcal Infections / immunology*
-
Pneumococcal Infections / prevention & control
-
Pneumococcal Vaccines / administration & dosage*
-
Pneumococcal Vaccines / immunology*
-
Randomized Controlled Trials as Topic
-
Serotyping
-
Streptococcus pneumoniae / classification
-
Streptococcus pneumoniae / immunology*
-
Treatment Outcome
-
United States
-
Vaccines, Conjugate / administration & dosage
-
Vaccines, Conjugate / immunology*
Substances
-
Antibodies, Bacterial
-
Bacterial Proteins
-
Heptavalent Pneumococcal Conjugate Vaccine
-
Pneumococcal Vaccines
-
Vaccines, Conjugate
-
CRM197 (non-toxic variant of diphtheria toxin)